Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
A total of 480 Chinese women aged 18-26 years old were enrolle，experimental group and the control group were randomly assigned in a ratio of 3:1. 360 Chinese women in the experimental group and 120 in the control group. All subjects enrolled in the upper arm deltoid muscle were injected with 3 doses of test vaccine or control vaccine according to the 0, 2, and 6 months immunization program.
HPV Infection|HPV-Related Cervical Carcinoma
BIOLOGICAL: Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)|BIOLOGICAL: 9-valent HPV vaccine（Gardasil 9）
Anti-HPV neutralizing antibodies GMT, 30 days after full immunization|Anti-HPV neutralizing antibody positive conversion rate（after full immunization 30 days）, 30 days after full immunization|Collect all SAEs, Vaccine-related and unrelated, through study completion, an average of 13 months|Collect AEs incidence, Vaccine-related and unrelated, Within 30 minutes of injection|Collect AEs incidence, All AEs: incidence of AEs related to vaccines and unrelated

The rate of Solicited for AE

Non-collective AEs: incidence of AEs related to vaccines and unrelated

AE level 3 and above: incidence of vaccine-related and unrelated AEs, Within 30 days after inoculation|collect AEs leading subject to withdrawal, Incidence of vaccine-related and unrelated AEs, through study completion, an average of 13months|collect All pregnancy conditions and pregnancy outcomes, collect pregnant woman Anti-HPV neutralizing antibody positive conversion rate and Anti-HPV neutralizing antibodies GMT, through study completion, an average of 13 months
A total of 480 Chinese women aged 18-26 years old were enrolle，experimental group and the control group were randomly assigned in a ratio of 3:1. 360 Chinese women in the experimental group and 120 in the control group. All subjects enrolled in the upper arm deltoid muscle were injected with 3 doses of test vaccine or control vaccine according to the 0, 2, and 6 months immunization program.